Business Context and Reporting Period
This Form 6-K, filed on April 15, 2003, serves as a notice to holders of American Depositary Receipts (ADRs) regarding the Annual General Meeting of Sanofi-Synthélabo scheduled for May 19, 2003. The filing summarizes the Group's financial performance and operational highlights for the fiscal year ended December 31, 2002. Sanofi-Synthélabo is a global pharmaceutical company headquartered in Paris, France, with significant operations in Europe, the United States, and other international markets.
Key Financial Metrics (Year Ended December 31, 2002)
- Revenue: Consolidated net sales totaled €7,448 million, representing a 14.8% increase on a reported basis and a 12.8% increase on a comparable basis.
- Profitability:
- Operating profit: €2,614 million (24.1% increase).
- Net income: €1,759 million (11.0% increase).
- Net income before exceptional items and goodwill amortization: €1,758 million (27.8% increase).
- Earnings per share (basic and diluted): €2.42 (28.7% increase).
- Margins:
- Gross margin: 81.5% (improved by 0.8 percentage points).
- Operating margin: 35.1% (improved from 32.5% in 2001).
- Effective tax rate: 28.9% (down from 34.8% in 2001).
- Cash Flow: Operating cash flow before changes in working capital was €2,260 million. Net cash and cash equivalents decreased by €1,340 million during the year to a net year-end position of €2,672 million.
- Dividends: A net dividend of €0.84 per share was declared, payable on June 2, 2003. Total dividends paid in 2002 were €473 million.
- Balance Sheet: Total assets were €9,459 million. Shareholders' equity increased to €6,035 million.
Material Changes Versus Prior Period
- Revenue Growth Drivers: Growth was primarily driven by three blockbuster products (Plavix, Aprovel/Avapro, and Stilnox/Ambien/Myslee), which generated €2,973 million in sales (up 32.1% on a comparable basis). The acquisition of 100% of Lorex Pharmaceuticals (Ambien rights) contributed significantly to US sales growth.
- Geographical Performance:
- Europe: Sales of €4,297 million (+11.8% comparable), despite cost-containment pressures in Italy and Germany.
- United States: Sales of €1,689 million (+17.5% comparable), boosted by the launch of Eloxatine and full consolidation of Lorex.
- Other Countries: Sales of €1,462 million (+10.3% comparable), with strong Asian growth offsetting Latin American economic difficulties.
- Expense Trends: Research and Development (R&D) expenses rose 18.1% to €1,218 million due to major clinical trials and new collaborations. Selling and general expenses increased 5.3% to €2,428 million, reflecting sales force expansion in the US.
- Exceptional Items: Exceptional items were minimal in 2002 (€10 million gain) compared to a €281 million gain in 2001, which included significant capital gains from asset disposals.
Guidance, Outlook, and Risks
Outlook: Management expects further strong growth in sales and profits for 2003, driven by the continued performance of blockbusters, the expansion of Eloxatine sales in the US, and strong results from Depakine, Solian, and Xatral. R&D investment will remain high, focusing on phase III trials for rimonabant, dronedarone, idraparinux, and zolpidem MR.
Risks and Contingencies:
- Forward-looking statements are subject to uncertainties, including the ability to expand profitably in the US and the success of R&D programs.
- Risks associated with protecting intellectual property rights, specifically regarding patent infringement proceedings for Plavix.
- Exposure to healthcare cost containment policies and pricing reforms in the US, France, and other European markets.
- Currency fluctuations, which had a net unfavorable impact of 2.5 percentage points on sales growth in 2002.
Corporate Actions: The Board was authorized to repurchase up to 10% of share capital (approx. 73.2 million shares) with a maximum budget of €5.86 billion. The age limit for the Chairman and CEO was raised to 68.
Investor Verification Checklist
- Verify the impact of the 100% consolidation of Lorex Pharmaceuticals on future US revenue streams.
- Monitor the progress of patent infringement litigation regarding Plavix against generic manufacturers (Apotex and Dr Reddy's).
- Assess the sustainability of R&D spending growth (€1,218 million) relative to future product launches.
- Review the execution of the share repurchase program and its impact on earnings per share.
- Confirm the timeline and regulatory approval status for key pipeline candidates: rimonabant, dronedarone, and idraparinux.